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Changes in Parkinson’s disease sleep symptoms and daytime
somnolence after bilateral subthalamic deep brain stimulation
in Parkinson’s disease
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Keyoumars Ashkan2
Introduction: Deep brain stimulation (DBS) markedly improves motor function in advanced Parkinson’s disease (PD), but its effect
on sleep is less clear. Patients and methods: Forty PD patients who had subthalamic DBS (STN-DBS) were identiﬁed from an on-
going non-motor naturalistic longitudinal study (NILS). All patients were followed up for at least 6 months, 26 patients had a 1 year
follow-up. A total PDSS score of 100 or less, a score in any PDSS-item of 6 or less, and a Epworth score of 10 or more were classiﬁed
as being signiﬁcant. Results: Forty-ﬁve percent of patients reported signiﬁcant improvement in the total PDSS score at 6 months,
and 35% at 12 months. In terms of magnitude, the total PDSS score at 6 months was signiﬁcantly improved from baseline while the
improvement at 12 months was not statistically signiﬁcant. The most frequently reported improvements were overall sleep quality
and maintenance of sleep. Some patients reported worsening of the total PDSS score. More than half of the patients reporting
daytime sleepiness at baseline had persistent sleepiness at 6 and 12 months. The mean Epworth Score did not improve because a
signiﬁcant number of patients without sleepiness at baseline reported new-onset sleepiness at 6 and 12 months. Neither
medication changes nor motor improvement were consistently related to sleep changes after DBS. Conclusion: Subthalamic DBS is
associated with a statistically and clinically signiﬁcant, but variable, improvement in sleep as measured by the PDSS. The most
frequent improvements were better overall sleep quality and better sleep maintenance.
npj Parkinson’s Disease  (2018) 4:16 ; doi:10.1038/s41531-018-0053-5
INTRODUCTION
The high prevalence and marked impact of non-motor symptoms
of Parkinson’s disease (PD) on quality of life1,2 are often
underappreciated by treating physicians.3,4 Sleep problems are
an integral aspect of the NMS of PD and are common in PD
patients, and become increasingly more frequent and severe in
advanced disease.5,6 Studies have reported that more than 95% of
advanced PD patients have problems with sleep7 while recent
studies in early PD have indicated an overall prevalence of about
49%.6 Practically any aspect of sleep may be affected, but the
most consistently reported sleep problems in untreated PD are
poor maintenance of sleep and sleep disturbed by nocturia.8,9
Dopaminergic therapy can improve aspects of sleep in PD
patients. Long acting agents or short duration preparations given
continuously (such as Apomorphine infusions) are particularly
beneﬁcial but even these strategies may not alleviate sleep
symptoms completely.10–12 Conventional treatments for sleep
problems, such as eszopiclone,13 clonazepam,14 and doxepin15
may improve sleep in PD patients; but need to be used carefully
since they have the potential to worsen daytime sleepiness,
cognition and balance in PD patients.
Deep brain stimulation (DBS) is an attractive treatment option
for patients where advanced therapies are indicated.16 While DBS
markedly improves motor functioning17,18 its effect on sleep is less
clear. There are only a handful of studies which utilize PD-speciﬁc
sleep scales for evaluation of sleep changes after DBS, and some
of these are compromised by small sample sizes and short
duration of post-surgery follow-up.
We surveyed long term changes in subjective reporting of sleep
symptoms (nocturnal and daytime) in 40 patients with Parkinson’s
disease who had Subthalamic Deep Brain Stimulation (STN-DBS),
using the PDSS and Epworth Sleep Scale. We conducted this study
with the aim of documenting changes in sleep symptoms after
STN-DBS. A secondary aim was to explore the inﬂuence of motor
improvement and medication changes on sleep symptoms after
DBS.
RESULTS
Demographics and baseline characteristics
Patient demographics and baseline characteristics are presented
in Table 1. A majority of patients (65%) had signiﬁcant overall
impairment of sleep (total score <= 100) at baseline. The most
frequent sleep symptoms were bad overall sleep quality (PDSS-1:
75%), difﬁculty maintaining sleep (PDSS-3: 82.5%), and getting up
to pass urine (PDSS-8: 80%). 40% (16/40) patients had signiﬁcant
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daytime sleepiness at baseline as measured by the Epworth
sleepiness scale.
Sleep changes after DBS
Forty-ﬁve percent (18/40) patients displayed signiﬁcant improve-
ment in the total PDSS score at 6 months, and 35% (9/26) at
12 months. In terms of magnitude, the total PDSS score improved
at 6 months by 23.5% (from a median score of 91.5 to 113.5, p=
0.001). The median score at12 months (median= 102) was higher
than that at baseline, but this difference was not statistically
signiﬁcant (p= 0.07).
The most frequently reported changes (Fig. 1) were improved
overall sleep quality (PDSS-1: 55% and 46% of patients at 6 months
and 12 months, respectively) and improved maintenance of sleep
(PDSS-3: 62.5% and 62% of patients at 6 and 12 months). Patients
also frequently reported improvement in tremor on waking (PDSS-
13: 40% and 27% of patients at 6 and 12 months) and painful
posturing of legs in the morning (PDSS-12: 30% and 38% of
patients at 6 and 12 months). At 6 months, the median
improvements in all of these aspects of sleep were statistically
signiﬁcant (Fig. 2). 1 year improvement showed a similar pattern,
but only the improvements in overall sleep quality, sleep
maintenance, and tremor on waking were statistically signiﬁcant,
although this may be because of small numbers who reached 1
year follow up.
7.5% (3/40) patients reported signiﬁcant worsening of the total
PDSS score at 6 months, and 19% (5/26) at 12 months. In addition,
for each sleep symptom, some patients reported deterioration
(Fig. 1). In particular, patients reported a very variable response in
terms of feeling tired and sleepy after waking up (PDSS-14).
Patients frequently reported feeling less tired and sleepy after
waking (47 and 35% at 6 months and 12 months) but, a
substantial number of other patients also reported being more
tired and sleepy on awakening (22.5% at 6 months and 35% at
12 months) and hence there was no improvement in the PDSS-14
median score.
Of the 16 patients with signiﬁcant daytime sleepiness at
baseline as measured by the ESS, 56% (9/16) had persistent
daytime sleepiness at 6 months and 81% (9/11) at 12 months. In
terms of magnitude, the Epworth Score did not improve because a
signiﬁcant number of patients without sleepiness at baseline
reported new-onset sleepiness at 6 months (33%, 8/24) and at
12 months (20%, 3/15).
There was no statistically signiﬁcant difference in the percen-
tage improvement in the PDSS total scores between patients who
showed moderate improvement of UPDRS scores after levodopa
challenge, as compared to those who showed marked
improvement.
Changes in medications after DBS
The mean LED dose decreased by 25% at 6 months (from 1051 ±
413mg at baseline to 786 ± 340mg) and by 30.5% (to 730 ±
417mg) at the 1 year follow-up. We did not detect an association
between decrease of dopaminergic medications and changes in
the total PDSS score. At 6 months, larger decreases in total LEDD
were weakly associated with a deterioration in the Epworth
Sleepiness score (Rho: −0.31, p= 0.049). No such relationship was
found at 12 months.
Changes in motor scores after DBS
As expected, the SCOPA-motor score improved in most patients.
The mean SCOPA-motor score improved by 35% at 6 months
(from 25.3 ± 10.1 to 16.4 ± 8.8, p < 0.0001) and by 40% at
Table 1. Demographics
Mean (SD) or number
(percentage)
Number of patients
Baseline 40
6 month follow-up 40
1 year follow-up 26
Gender (Females) 15 37.5%)
Age at onset of symptoms 48.7 ± 7.7
Age at the time of DBS surgery 59.6 ± 8.3
Duration of symptoms before DBS
surgery (years)
10.7 ± 4.5
PDSS-total ( <= 100) 26 (65%)
PDSS-1: Overall sleep quality 30 (75%)
PDSS-2: Difﬁculty falling asleep 15 (37.5%)
PDSS-3: Difﬁculty staying asleep 33 (82.5%)
PDSS-4: Restlessness of legs or arms 18 (45%)
PDSS-5: Fidgeting in bed 19 (47.5%)
PDSS-6: Distressing dreams 9 (22.5%)
PDSS-7: Distressing hallucinations at
night
1 (2.5 %)
PDSS-8: Getting up to pass urine 32 (80%)
PDSS-9: Urinary incontinence due to
immobility
4 (10%)
PDSS-10: Numbness or tingling of
arms/legs
10 (25 %)
PDSS-11: Muscle cramps while sleeping 18 (45%)
PDSS-12: Painful posturing on waking 17 (42.5%)
PDSS-13: Tremor on waking 21 (52.5%)
PDSS-14: Tired and sleepy on waking 23 (57.5%)
PDSS-15: Unexpectedly falling asleep
during the day
17 (42.5%)
Epworth sleepiness scale 16 (40%)
Fig. 1 Percentage of patients reporting a change in PDSS sub-scores at 6 and 12 months
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12 months (to 15.2 ± 8.15, p < 0.0001). No clear relationship was
discernible between improvement in SCOPA-motor scores and
global improvement of sleep (total PDSS score) at either 6 or
12 months (Spearman’s correlation).
DISCUSSION
In this study, subthalamic DBS was followed by a statistically and
clinically signiﬁcant, but variable, improvement in sleep as
measured by the PDSS. The most frequent improvements were
better overall sleep quality and better sleep maintenance.
However, a variable but signiﬁcant proportion of patients
experienced deterioration in different aspects of sleep (Fig. 1).
Sleep improvement after DBS did not correlate with improvement
in UPDRS scores after levodopa challenge testing prior to DBS
insertion, medication changes after DBS or motor improvement
after DBS. At this point, we believe that it is reasonable to counsel
patients that while different aspects of their sleep may improve or
deteriorate after DBS; the most likely possibility is that they will
have an overall improvement in their sleep.
The present study is the largest study utilizing a PD-speciﬁc
sleep symptom questionnaire. A previous large study of sleep
symptoms in PD after unilateral STN-DBS did not utilize a PD-
speciﬁc sleep questionnaire, although the results reported were
comparable to the present study.19 Polysomnography (PSG)
studies of PD patients after DBS have documented a reduction
in sleep disturbance, decrease in wakefulness after sleep onset,
improvement in sleep efﬁciency and total sleep time, and
increased REM sleep.20–23 These PSG changes are compatible
with the changes documented in our study.
There is considerable variation in the results of previous studies
utilizing the PDSS on post-DBS sleep changes24–27 (Table 2). The
most consistent and signiﬁcant change is seen in sleep
maintenance (PDSS-3), in keeping with our study. It is possible
that patients interpret this change as an improvement in their
overall sleep quality (PDSS-1). In addition, we also noted
substantial improvement in tremor and painful posturing after
waking (PDSS-12 and 13), which is likely related to better control
of motor symptoms by DBS even before the morning dose of
dopaminergic medication is ingested.
Previous research has suggested that a marked decrease in
dopaminergic medications (by 79% or more) after STN-DBS may
worsen or lead to the emergence of restless legs syndrome and
REM behavior disorder.28,29 In this study, a signiﬁcant number of
patients developed worsening restlessness of legs, distressing
dreams and hallucinations at night (Fig. 2: PDSS-4, PDSS-6, and
PDSS-7) even though the decrease in dopaminergic medications
was modest. There is uncertainty regarding the relationship
between leg motor restlessness in PD and true RLS,30,31 and
polysomnography is required for the deﬁnitive diagnosis of RBD.32
Hence, these ﬁndings should be interpreted with caution.
The PDSS assesses nocturnal problems, sleep disturbances and
excessive daytime sleepiness and is composed of 15 items,
addressing nocturnal symptoms commonly associated with PD
(insomnia, nocturia, nocturnal motor symptoms, etc.). Each item is
rated on a visual analog scale (VAS) from 0 (severe or always
present) to 10 (never or not present). The total score is obtained
by summing the items. The time frame is the previous week. It is
speciﬁc for PD, is extensively used and validated and has been
shown to be responsive to changes and is recommended by the
MDS Task Force.33 Studies have also suggested data from PDSS
correlate with PSG based datasets and worldwide reports from
studies using PDSS indicate that scores below PDSS-total of 100
indicate abnormal sleep. The PDSS is useful to identify PD patients
who will have abnormal PSG recordings,34 but the correlation
between subjective and objective measures of sleep can be
imperfect.35 We believe that subjective and objective measures of
sleep are complimentary; neither one is necessarily “superior” to
the other. Although it is clear that subjective sleep assessments
are fundamental to complaints of insomnia and non-restorative
sleep, two conditions associated with considerable morbidity and
impairment in PD.36
Arnulf et al.20 found that night-time awakenings, a normal
phenomenon, were often followed by dystonia and extended
awakenings. They hypothesized that the continuous nature of DBS
stimulation may provide better motor control at night, preventing
such extended awakenings. Our univariate analyses indicated that
improvement in motor function was not sufﬁcient for an
improvement in sleep maintenance; however its contribution
needs to be evaluated with multivariate analysis in a larger
sample. We detected an increase in daytime sleepiness associated
with reduction of high doses of total LEDD. This is possibly the
result of falling in the trough of the sleep-response to levodopa,
wherein more moderate doses of levodopa are associated with
sleepiness and higher doses with better wakefulness, as described
by Bliwise et al.37
In addition to motor improvement and medication changes,
multiple other factors may affect post-DBS sleep, including
changes in depressive symptoms38 and possibly a direct effect
of DBS on sleep structures. It is a difﬁcult task to assess the relative
contributions of these factors. GPi-DBS is usually followed by
smaller decrease in dopaminergic medication39and it may be
possible to gain a better understanding of the relative importance
of motor improvement without this additional confounder. In a
randomized trial of GPi-DBS versus STN-DBS,39 the magnitude of
sleep improvement measured by PDSS was similar in both groups,
possibly indicating a durable effect common to both GPi and STN
DBS that surpasses any effect of dopaminergic medication
withdrawal.
There are limitations to our study. First, we did not assess sleep
architecture formally, as discussed above. However, the globally
validated PDSS use does offset the lack of PSG and additionally
allows inclusion of motor and other PD symptoms which affect
sleep. Second, we did not assess the effect of depression. Changes
in mood which may occur in some patients after STN-DBS38 could
have worsened sleep symptoms40 and diluted our results. Third,
we did not undertake multivariate analysis. In our view, multi-
variate analyses could be misleading given the relatively small
patient population. Since this was a preliminary study, we did not
use a multiple comparison correction such as Bonferroni, which
Fig. 2 Median and range of PDSS sub-scores at baseline, 6 and 12 months. (*6 month score statistically different from baseline, **both 6 and
12 month scores statistically different from baseline)
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can substantially increase the chance of a type II error.41 Finally,
the cut-offs we used for deﬁning signiﬁcant change in sleep
symptoms need to be prospectively validated.
In conclusion, our study conﬁrms improvement in some sleep
symptoms after STN-DBS, in particular overall sleep quality and
sleep maintenance. Our data indicates that improvement in motor
function is not sufﬁcient for sleep improvement. Further studies
need to focus on the reasons for these improvements with the
goal of reﬁning DBS and medication management strategies after
STN-DBS to maximize sleep improvement.
METHODS
Patients
40 patients who had STN-DBS for Parkinson’s disease and were enrolled in
the on-going non-motor naturalistic longitudinal study (NILS, UK clinical
research network number 10084). The NILS study received ethical approval
from all local Research Ethics Committees at each centre, and all patients
provided informed written consent for inclusion in the study. All patients
were followed up for at least 6 months, 26 of these patients also had a 1
year follow-up.
All patients met British Brain Bank criteria42 for PD, and were selected for
DBS due to insufﬁcient control of their motor symptoms by medication.
Pre-surgery response to levodopa was veriﬁed in all cases by a >30%
improvement in the Uniﬁed Parkinson’s Disease Rating Scale (UPDRS)-III
motor score after a standard levodopa challenge dose. None of the
patients had signiﬁcant psychiatric illnesses or dementia which would
preclude DBS implantation. All patients had pre-operative full multi-
disciplinary assessment by our dedicated DBS team, which includes a
neuropsychologist and a neuropsychiatrist.
All patients in this study had bilateral subthalamic implantation of DBS
electrodes, followed by initiation of stimulation within 6 weeks. DBS
programmer settings were changed per clinical requirements at the
discretion of the treating physician / DBS specialist nurse. Patients were
evaluated at ﬁxed intervals per the NILS protocol: within one month before
DBS surgery, 6 months after surgery, and yearly thereafter. All 40 patients
had a baseline and 6 month evaluation. At the present time, 26 patients
have had the 12 month evaluation.
Measurement instruments
1. Sleep symptoms were assessed by the Parkinson’s Disease Sleep
Scale (PDSS),36 a patient reported 15 item scale with each item
weighed from 0 to 10. Lower scores on each item represent worse
symptoms: 0 indicates that the patient “always” has the symptom
and 10 represents an answer of “never”. Correspondingly, the total
PDSS score varies between 0 (worst) and 150 (best).
2. Daytime sleepiness was assessed using the Epworth Sleepiness
Scale,43 which is an 8-item scale that assesses the likelihood of
falling asleep while performing common tasks during the day. A
score of 0 indicates no daytime sleepiness, while the maximum
score of 24 indicates the highest level of daytime sleepiness in all
tested situations.
3. Motor improvement was measured by the motor subpart of the
SCOPA scale (SCOPA-motor),44 a 21 item scale which correlates
strongly with the corresponding subpart of UPDRS-III.44,45 Higher
scores on SCOPA-motor represent worse motor symptoms, the
maximum score is 75.
Categorization of scores
Patients with a total PDSS score of 100 or less,10 a score in any PDSS-item
of 6 or less, and a Epworth score of 10 or more46 were classiﬁed as having
signiﬁcant problems. A change of the total PDSS score by 20 points or
more, or in one of the sub-scores by 2 points or more was considered
clinically signiﬁcant. Follow-up scores were classiﬁed as improved, stable or
worse as compared to the baseline scores. The criteria for deﬁning
clinically signiﬁcant change in PDSS scores were based on our clinical
experience and have not been formally validated. The percentage
improvement in UPDRS score after levodopa challenge was categorized
into two categories: “Moderate” if the improvement was between 30–65%
and “Marked” if the improvement was 65% or above.
Medication changes
The levodopa equivalent daily dose (LEDD) was computed according to
the widely accepted method described by Tomlinson et al.47
Statistical analysis
Data analysis was done in Stata 12 (Stata Corp, Texas). Normality was
tested using the Shapiro-Wilk test. For pre-DBS and post-DBS comparisons,
the Wilcoxon signed-rank test was used for comparing non-normally
distributed variables and the paired student t-test was used for normally
distributed variables, corresponding non-paired tests were used for other
comparisons.
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